ADMA Biologics is an end-to-end commercial biopharmaceutical company leading a new age of manufacturing, marketing, and commercializing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for certain infections. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart.
With three FDA-approved products, including ASCENIV™ (Immune Globulin Intravenous, Human–slra), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (Hepatitis B Immune Globulin, Human), ADMA’s mission is to continue to successfully develop and commercialize plasma-derived, human immune globulins targeted to specific patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.
Product Approval Dates
01‐APR‐2019 Immune Globulin Intravenous, Human‐slra
19‐DEC‐2012 Immune Globulin Intravenous (Human)
23‐OCT‐2001 Hepatitis B Immune Globulin (Human)